Spero Therapeutics (SPRO) Cash from Financing Activities (2016 - 2023)

Spero Therapeutics (SPRO) has 8 years of Cash from Financing Activities data on file, last reported at $1000.0 in Q4 2023.

• For the quarter ending Q4 2023, Cash from Financing Activities fell 99.99% year-over-year to $1000.0; the trailing twelve-month figure through Dec 2024 stood at $221000.0 (changed 0.0% YoY), and the FY2023 full-year result was $221000.0, up 100.75% from the prior year.
• Cash from Financing Activities for Q4 2023 stood at $1000.0, down from $220000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $77.2 million in Q3 2020 and bottomed at -$53.7 million in Q2 2022.
• The 5-year median for Cash from Financing Activities is $5.9 million (2019), against an average of $11.2 million.
• The widest annual swing landed in 2020, when Cash from Financing Activities jumped 772050.0%; it then slumped 32050.6% in 2022.
• A 5-year view of Cash from Financing Activities shows it stood at $5.6 million in 2019, then soared by 187.37% to $16.1 million in 2020, then jumped by 212.92% to $50.3 million in 2021, then sank by 71.84% to $14.2 million in 2022, then plunged by 99.99% to $1000.0 in 2023.
• The last three Cash from Financing Activities figures came in at $1000.0 (Q4 2023), $220000.0 (Q3 2023), and $14.2 million (Q4 2022), per Business Quant data.

Peer Comparison